Datapoint: Eli Lilly to Test Emgality Against Nurtec ODT

Eli Lilly and Co. last week said it is planning a head-to-head trial for its once-monthly injectable migraine drug Emgality against Biohaven Pharmaceuticals’ Nurtec ODT, an oral therapy taken every other day. Lilly is aiming for a 50% reduction in the number of headache days trial patients experience per month. Nurtec ODT is the only drug that is FDA-approved for both immediate migraine treatment and migraine prevention, and holds covered or better status under the pharmacy benefit for 78% of all insured lives. It is not covered for 18.4% of lives. Meanwhile, Emgality is 92% covered or better for migraine prevention.

SOURCE: MMIT Analytics, as of 6/17/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today